转移性结直肠癌一线治疗的疗效与毒性性别差异:ARCAD数据库18,041例分析
基于ARCAD CRC数据库27项随机试验的18,041例转移性结直肠癌患者数据,评估一线化疗联合或不联合靶向治疗的疗效与毒性性别差异。结果显示男女总生存和无进展生存无显著差异,但女性化疗相关恶心、呕吐及中性粒细胞减少发生率更高,男性皮疹更常见。
要点
- 男女mCRC患者一线治疗的总生存和无进展生存无显著差异。
- 女性化疗相关恶心、呕吐及中性粒细胞减少发生率显著高于男性。
- 男性皮疹(含靶向治疗相关)发生率显著高于女性。
核心结论
- 尽管女性化疗相关毒性更高,但一线治疗疗效在男女之间相似。
- 皮疹在男性中更常见,提示性别对毒性谱有双向调节作用。
研究设计与样本
- 研究纳入ARCAD CRC数据库中27项随机试验,分析18,041例转移性结直肠癌患者的基线数据。
- 疗效分析纳入15,271例患者,按治疗组分为单纯化疗、化疗联合贝伐珠单抗、化疗联合表皮生长因子受体抑制剂三组。
- 采用Kaplan-Meier法估计总生存和无进展生存,使用研究分层Cox模型校正年龄、体能状态、体重指数和化疗 backbone 后评估性别相关性。
临床怎么用
- 临床实践中应关注女性mCRC患者化疗相关恶心、呕吐及中性粒细胞减少的更高风险,并采取相应预防和支持措施。
- 男性患者使用靶向治疗时需注意皮疹的监测与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Greater toxicity of adjuvant chemotherapy in females has been reported previously, but the impact of patients' sex on chemotherapy (CT)+/-targeted therapies for non-resectable, metastatic colorectal cancer (mCRC) has remained unclear. We compared efficacy and toxicity of first-line chemotherapy, with or without targeted therapies, between male and female mCRC patients. METHODS: Twenty-seven randomized trials from the ARCAD CRC database were included. Primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), overall response rate, toxicity (according to NCI-CTCAE). Analyses were performed within three treatment groups: A) CT alone, B) CT+bevacizumab, and C) CT+epidermal growth factor receptor inhibitor. OS and PFS were estimated using Kaplan-Meier method. Associations with sex were assessed using study-stratified Cox models adjusted for age, performance status, body mass index, and CT backbone. RESULTS: Baseline data from 18,041 patients were analysed; among 15,271 included in outcome analyses, no sex differences in OS or PFS were observed. Adjusted OS hazard ratios (95% confidence interval) for females versus (vs.) males were: A: 1.01 (0.95-1.08, P = .69), B: 0.96 (0.89-1.04, P = .36), C: 0.97 (0.87-1.10, P = .67). Females experienced higher toxicity, including grade 1-4 and 3-4 nausea (71.8% vs. 60.5% and 7.5% vs. 4.8%), vomiting (47.7% vs. 35.5% and 6.6% vs. 4.4%), and neutropenia (52.4% vs. 44.4% and 29.2% vs. 18.8%) (P < .001). Conversely, rash (grade 1-4 and 3-4) was more frequent in males (29.6% vs. 24.3% and 5.1% vs. 3.7%, P < .001). CONCLUSIONS: Despite higher chemotherapy-related toxicity in females, treatment efficacy was similar between sexes. Rash was more common in males, highlighting that patients' sex modulates toxicity profiles in both directions. Strategies to reduce adverse events in female patients are warranted.
引用
- Wagner AD, Raeisi M, Rakez M, et al. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database. Eur J Cancer. 2026. PMID: 41903302. doi:10.1016/j.ejca.2026.116694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。